Oncocyte Hosting Key Opinion Leader Call on Novel Biomarkers in Identifying Appropriate Responders to Immune Checkpoint Inhibitors

IRVINE, Calif., April 14, 2021 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that it will host a key opinion leader (KOL) call on novel biomarkers in identifying appropriate responders to immune checkpoint inhibitors on Monday, April 19, 2021 at 11:30am Eastern Time.

The event will feature a presentation by KOLs David Gandara, MD, UC Davis Comprehensive Cancer Center, and Mamta Parikh, MD, MS, UC Davis Comprehensive Cancer Center, who will present an overview of the use and limitations of currently clinically available biomarkers, such as PD-L1 and tumor mutational burden (TMB), in identifying responders to immunotherapies, specifically immune checkpoint inhibitors (ICI) that are FDA-approved for a broad range of solid tumors. New data will also be discussed, presented for the first time during an oral symposium at the 2021 American Association for Cancer Research (AACR) Annual Meeting, showing that DetermaIO, a 27-gene test that assesses the tumor microenvironment to identify immunotherapy responders, has strong performance in identifying responders to atezolizumab in bladder cancer, as measured by overall survival rates in DetermaIO-positive patients who received ICI. This adds to previously presented data in non-small cell lung cancer and triple-negative breast cancer that demonstrates incremental utility beyond PD-L1 and TMB in identifying responders to all currently approved ICIs. Evidence now presented for three different cancers suggests a potential pan-cancer application for the test.

Drs. Parikh and Gandara will be available to answer questions following the formal presentations.

To register for the call, please click here.

Mamta Parikh, MD, MS is a medical oncologist and assistant professor at the University of California, Davis. She specializes in the medical treatment of genitourinary malignancies including kidney/renal cell, bladder, prostate, ureteral cancers, and germ cell tumor cancers. Her clinical research interests focus on prostate, kidney, and bladder cancer. She is the principal investigator on numerous clinical trials, is the national principal investigator on an NCI-sponsored trial of a novel ATR inhibitor in combination with chemotherapy in advanced solid tumors, and collaborates with basic researchers on translational clinical research projects. She is an active member of the California Cancer Consortium and the Southwest Oncology Group.